发明名称 |
Epo knockout GFP anemic mouse |
摘要 |
The present invention relates to a model animal spontaneously developing anemia. More specifically, the invention relates to a transgenic non-human mammal spontaneously developing anemia associated with a postnatal decrease in production of erythropoietin (Epo), Epo-producing cells prepared from the transgenic non-human mammal, and a screening method using the Epo-producing cells. |
申请公布号 |
US9180207(B2) |
申请公布日期 |
2015.11.10 |
申请号 |
US201214008703 |
申请日期 |
2012.03.29 |
申请人 |
TOHOKU TECHNO ARCH CO., LTD. |
发明人 |
Yamamoto Masayuki;Minegishi Naoko;Yamazaki Shun |
分类号 |
A01K67/027;A01K67/033;A61K49/00;G01N33/50 |
主分类号 |
A01K67/027 |
代理机构 |
Pearne & Gordon LLP |
代理人 |
Pearne & Gordon LLP |
主权项 |
1. A transgenic mouse developing anemia after birth by genetic modification, wherein the genetic modification comprises:
(a) a homozygous knockout of an endogenous erythropoietin (Epo) gene in the genome of the mouse; and (b) introduction of an extraneous Epo gene, in a chromosome of the mouse, as a transgene, the transgene being a region from 3.3-kb upstream to 4.5-kb downstream of a transcription start site of the Epo gene, wherein: the mouse is hemizygous or homozygous for the extraneous Epo gene; expression of the extraneous Epo gene rescues the mouse from lethality by a shortage of Epo or anemia associated therewith before birth; expression of the extraneous Epo gene in the kidney is suppressed after birth; and the mouse was generated from a fertilized egg deposited under accession number FERM BP-11347. |
地址 |
Miyagi JP |